Government may lift price cap on cancer drugs making them costlier by up to 50%
Hetero partners with Richter to develop, market Semaglutide injection globally- Pharma in her DNA, Wockhardt scion ready for deep dive in the US
- Duty relief may be extended for petrochemical inputs for pharma
- FeaturedUTI Nifty 50 Index Direct-G-4.14-9.65-6.748.68
- -4.132.105.1821.40
- 1.23-3.52-2.0114.62
- Insider trading: Supreme Court upholds SAT clearance to Biocon MD
- SBI in $1 billion funding for Sun Pharma’s US deal
- Indian cancer patients battle shortage of key drugs as platinum costs surge
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
- India willing to open its market to high-quality, innovative pharma products, says commerce minister
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply
- Regulator, cos discuss price hike for some cancer drugs
- Drug companies directed to step up vigil on adverse reactions
- Manipal Health takes Bengaluru hospital building on long-term lease
- Pharma exports to US seen muted this year
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight loss
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun Pharma
- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
Top Mutual Funds
3 M(%)
6 M(%)
1 YR(%)
3 YRS(%)